Drops (SLIT) programs for physicians compared
Choosing a sublingual immunotherapy program starts with a practice decision, not a brand ranking: will your clinicians prescribe and manage treatment, order patient-specific treatment sets, or refer patients for another clinical team to assess and treat? These are different purchases. This comparison separates the public offers of Allergychoices / the La Crosse Method, AllergyEasy, Wyndly, Curex and Serologix so that a practice can request the right clinical, operational and financial documents before committing.
For U.S. physicians evaluating allergy-drop program implementation or a referral pathway. Original public provider and patient pages were checked on October 12, 2026. Company pages establish what a business offers, not independent clinical efficacy, licensure verification or approval of an individual patient. “Not published” means not found in the cited public pages checked for this comparison; it does not mean unavailable by inquiry. Public availability does not establish that a program is accepting your specialty, location or patient population. This is a physician-program comparison, not a ranking of dispensing pharmacies or a treatment protocol. Clinical and second-reader approval remain pending.
Choose the service model before comparing vendors
A clinical or protocol program supplies an approach to assessment and treatment, with some combination of education and case support. Practice enablement supplies operational tools such as testing, prescription forms, patient materials or marketing. Compounding and fulfillment prepare and deliver a prescribed product. A referral or telemedicine pathway sends the patient to another clinician for the treatment decision. A company may offer more than one layer, but the layers should not be treated as interchangeable.
Allergychoices and AllergyEasy publish offers intended to help local practices prescribe allergy drops. Serologix publishes a patient-specific compounding and electronic-ordering service for medical practices. Wyndly publishes an in-office testing partner offer linked to care from Wyndly doctors. Curex publishes separate clinic-testing enablement and patient-referral offers. Those last two models are not, on the cited evidence, a license for your practice to run their treatment protocols under your own prescribers.
Choose the clinical endpoint first. A practice that wants to retain prescribing needs explicit education, decision support, follow-up capacity and prescription authority. A practice that wants an external care pathway needs a referral acceptance policy and a reliable way to receive clinical information back. Neither model eliminates the referring clinician’s need to assess concerns that require local or specialist care.
Provider × program model: public offers checked October 12, 2026
The table records the current public offer at the source-check date, not a verified contract or a promise of enrollment. Read the profiles below for fit, limitations and precise questions to resolve before implementation. Published product or patient prices are not automatically practice-program fees.
On smaller screens, scroll the table horizontally to read every column.
| Provider / program | Substantiated public model | Local practice and clinical handoff | Published support / workflow | Cost and contract scope |
|---|---|---|---|---|
| Allergychoices / La Crosse Method | Protocol-based practice implementation; diagnostics, clinical support and a pharmacy option. | Local provider assesses and prescribes patient-specific treatment; vendor support does not replace that clinician. | Protocol access; pharmacist and physician-advisor support; ordering, prior-order management and patient-tracking tools. | Service page states “No contracts.” Pharmacy prescription pricing is provided by phone ((866) 793-1680, opt 3). A complete practice implementation fee schedule and detailed service terms: Not published in the cited pages. |
| AllergyEasy | Local-practice testing and prescribing program, described by the company as turnkey. | Local provider completes intake, evaluates patients and prescribes; the provider page says a licensed compounding pharmacy prepares and ships drops. | Optional testing program; faxable prescription form; clinical support, patient resources, marketing materials and patient referrals. | Start-up packages and in-house financing are advertised. Package amounts, financing conditions and complete practice contract terms: Not published in the cited pages. |
| Wyndly provider / partner offer | In-office allergy testing partner pathway with result review and patient care from Wyndly doctors. | Partner practice offers testing; Wyndly doctors review results with the patient. This is not evidence of a local-prescriber turnkey SLIT implementation program. | Trial-kit pathway and partner contact; patient service publishes doctor-guided telehealth therapy and delivered treatment. | Partner page publishes per-kit commercial terms, separate from patient treatment charges. Full partner eligibility, contract and local-prescriber training scope: Not published in the cited pages. |
| Curex clinic services | Clinic skin-testing enablement and a separate referral pathway for test review, at-home immunotherapy and asthma care. | The referral offer routes treatment assessment to Curex; the patient service describes telemedicine prescribing and specialty-pharmacy preparation. | A clinic diagnostics offer is public, but implementation curriculum, staffing commitments and shared-record service levels: Not published in the cited pages. | Patient plans are not practice pricing. Complete clinic-program charges, referral commercial terms and contract conditions: Not published in the cited pages. |
| Serologix | Patient-specific SLIT compounding and electronic-ordering enablement for medical practices. | Ordering physician specifies the treatment set. Public pages do not establish a replacement clinical service for the patient. | Web ordering with company-described compatibility tools; allergy/immunology specialist and PharmD consultation on formulation. | Full SLIT price schedule, formal prescriber-training package and practice-specific service agreement: Not published in the cited pages. General website sale terms are not a complete clinical-services contract. |
- Allergychoices — Our Service Approach
- Allergychoices — Clinical Practice Support
- Allergychoices — Allergychoices Pharmacy
- AllergyEasy — Become a Provider
- Wyndly — Partner FAQ
- Wyndly — Allergy Shot Alternative with Sublingual Treatment Plans
- Curex — Immunotherapy Partners
- Curex — About Curex: Online Allergy and Asthma Clinic
- Serologix — Sublingual Immunotherapy Compounding
- Serologix — Company Info and Service Terms
Where each program is ahead
Every program in this comparison does something well. Match those strengths to the care model your practice wants to run.
On smaller screens, scroll the table horizontally to read every column.
| Provider / program | Where it is ahead | Best fit |
|---|---|---|
| Allergychoices / La Crosse Method | A named protocol family covering environmental, food and preseasonal treatment; pharmacist and physician-advisor support with ordering, prior-order and patient-tracking tools; patient-specific pharmacy preparation with counseling and lot tracking; published “No contracts” service statement. | Practices that want to keep prescribing in-house, including food allergy, with ongoing protocol support. |
| AllergyEasy | A concrete onboarding sequence for local providers; optional environmental and food testing kits; faxable prescription form; marketing materials, patient resources and patient referrals; advertised start-up packages with in-house financing. | Practices that want a packaged testing-and-prescribing start with marketing help. |
| Wyndly provider / partner offer | Publishes concrete per-kit commercial terms for in-office testing; Wyndly doctors review results with the patient and provide ongoing telehealth care, so the practice does not need to build its own immunotherapy service. | Practices that want to offer testing and hand treatment to an external clinical team. |
| Curex clinic services | Two separate public offers: clinic skin-testing enablement and a referral pathway for test review, at-home immunotherapy and asthma care; telemedicine prescribing with specialty-pharmacy preparation; several patient testing pathways. | Practices that want an external allergy-and-asthma care pathway alongside in-office testing. |
| Serologix | A focused formulation-and-ordering service: patient-specific treatment sets to the ordering physician’s specifications, web ordering with cross-reactivity and compatibility tools, and consultation with an allergy/immunology specialist and a PharmD. | Practices with their own clinical expertise that want a lean compounding and ordering partner. |
- Allergychoices — About the La Crosse Method Practice Protocol
- Allergychoices — Clinical Practice Support
- Allergychoices — Allergychoices Pharmacy
- Allergychoices — Our Service Approach
- AllergyEasy — Become a Provider
- Wyndly — Partner FAQ
- Wyndly — Allergy Shot Alternative with Sublingual Treatment Plans
- Curex — Immunotherapy Partners
- Curex — About Curex: Online Allergy and Asthma Clinic
- Serologix — Sublingual Immunotherapy Compounding
- Serologix — Company Info and Service Terms
Decision criteria that change the purchase
- Clinical ownership: identify the clinician who diagnoses, selects allergens, signs prescriptions, approves changes and follows the patient. Do not equate vendor case advice with transfer of clinical responsibility.
- Population and scope: specify environmental allergic rhinitis, asthma considerations and any separate food-allergy service. Obtain exclusions, specialist-escalation criteria and the exact scope available to your prescribers.
- Education and competence: ask for a curriculum, prerequisites, supervised case review, staff education and evidence of completion. “Clinical support” does not by itself establish a complete training program or a professional credential.
- Workflow: evaluate testing, result interpretation, order entry, prescription approval, patient counseling, refill authorization and follow-up documentation. Demonstrate the handoffs rather than relying on “turnkey.”
- Support: distinguish routine formulation consultation, patient service, urgent clinical advice and emergency care. Ask who responds, when, in what channel and what gets documented in your chart.
- Total cost: separate practice start-up and recurring charges, testing supplies, staff time, patient visits, pharmacy charges and any patient subscription. Model unpaid follow-up work and patient drop-out without assuming advertised revenue.
- Continuity: require a plan for adverse events, interrupted care, prescriber departure, record export and program termination. Decide who tells the patient where to obtain the next clinical assessment.
Allergychoices / La Crosse Method: protocol and practice support
What is published: the La Crosse Method page describes a family of patient-specific SLIT protocols, including environmental, food and preseasonal treatment. The service approach includes help using existing diagnostics or implementing skin testing, clinical practice support, practice-growth materials and a pharmacy option. These are implementation services for a practice, rather than simply a consumer referral destination.
Visible strength and fit: a practice seeking a named protocol with ongoing access to pharmacists and physician advisors can evaluate several implementation layers in the public offer. The clinical-support page specifically describes help with clinical and antigen-related questions, prescription ordering, previous orders and patient tracking. The pharmacy page describes patient-specific preparation, counseling and lot tracking. This makes the offer relevant to a local clinician who intends to remain the prescriber.
Training and prescription workflow: public pages establish access to protocol expertise and case consultation. They do not, by themselves, establish the curriculum, competency assessment, course availability or time commitment for your team. Ask for those documents. The described pharmacy workflow prepares a named-patient prescription according to the provider’s prescription; request a demonstration of how test results, selected allergens, approval of changes and refill review enter that workflow.
Costs and terms: the service page says “No contracts” and makes low-overhead implementation claims. The pharmacy page directs pricing questions to the pharmacy by phone; that is not an all-in practice implementation budget. A full schedule covering education, diagnostic supplies, optional services and internal practice work is Not published in the cited pages. Ask what the no-contract statement covers and what separate pharmacy, portal, data and payment terms apply. Do not treat it as evidence of zero local staff effort.
Limits to resolve: public access to a broad protocol family does not establish that every clinician or patient is eligible for every component. Request environmental and food scope separately, the escalation path for complex cases and the evidence relevant to the proposed formulation. The company’s protocol history and outcome-validation claims are not FDA approval of compounded drops or a head-to-head comparison with the other programs.
- Precontract question: what education and case review are required before our first environmental prescription, and what additional requirements apply before any food-allergy service?
- Precontract question: which follow-up tasks belong to our clinicians, which are pharmacy counseling or adherence support, and how are consultations and prescription changes returned to our chart?
AllergyEasy: testing and prescribing within the local practice
What is published: the provider page invites clinicians to complete a provider intake form, use an optional testing program and prescribe drops. It describes environmental and food testing kits, a faxable prescription form, clinical support, marketing supplies, patient resources and patient referrals. It says a licensed compounding pharmacy prepares and ships the patient’s drops. AllergyEasy’s program offer should not be confused with an independently verified dispensing-pharmacy license.
Visible strength and fit: a practice seeking a locally delivered testing-and-prescribing pathway can review a concrete onboarding sequence and a list of practice-support materials. Optional testing supplies may be useful to a practice evaluating a new diagnostic workflow. Whether your existing diagnostic methods meet the program’s requirements still needs confirmation.
Training and prescription workflow: the public provider page describes assistance in prescribing but does not publish a complete education syllabus, competency standard or support response commitment. Request training for prescribers and testing staff, the actual prescription documentation and the process for communicating revisions to the dispensing entity. A faxable form is an order channel, not a substitute for patient-specific clinical judgment.
The current homepage describes a broad “universal serum” approach, while the provider page describes a comprehensive inhalant mix and local prescribing. Ask for the actual formulation-selection rules, concentration documentation and rationale for each patient before assuming that the program is fully individualized or that every component of a broad mix is clinically relevant. The inhalant guideline recommends treating allergens that correlate with the patient’s history and are confirmed by testing; the number of antigens or cross-reactivities is not an outcome measure.
Costs and terms: discounted start-up packages and in-house financing are advertised, but the cited pages do not publish package amounts, financing conditions, recurring practice charges or a complete contract. Those items are Not published, not estimated. Ask whether clinical support, materials, testing replenishment, prescription processing and discontinuation costs are included in the quote.
Limits to resolve: the company markets food treatment and describes testing as optional. That does not remove the clinician’s need for a supported diagnosis and a specialist-led food-allergy assessment. Broad marketing statements about pregnancy, young children, asthma or safety should not be adopted as universal patient-selection rules. Confirm the exact offered service, exclusions and clinical evidence rather than transferring general SLIT literature to a particular mixture.
- Precontract question: how does the proposed mix address clinically relevant allergens in our patients, and how are exceptions or changes authorized?
- Precontract question: which named entity dispenses the prescription, and what training, consultation and patient follow-up obligations remain with our practice?
Wyndly: a verified testing-partner and external-care pathway
What is published: an actual Wyndly Partner FAQ is publicly available. It invites practices to offer allergy testing in the office, provides a trial-kit pathway and states that Wyndly doctors review results with patients. The consumer site describes doctor-guided telehealth therapy, delivered treatment and care for listed environmental allergens. Wyndly therefore belongs in this comparison as a substantiated provider-facing offer, not merely an assumed partnership.
Visible strength and fit: the distinction between office testing and subsequent review by Wyndly doctors is useful for a practice that wants a handoff rather than building an internal immunotherapy-prescribing service. The public partner page also provides specific kit commercial terms, making the testing component more concrete than a generic invitation to refer.
Workflow and support: the public page establishes testing in the partner office and result review with the patient by Wyndly doctors. It does not establish that partner clinicians receive a treatment protocol, prescribe Wyndly therapy themselves or get comprehensive SLIT implementation training. Local-prescriber training, shared-record integration, referral-status reporting and a clinical communication service level are Not published in the cited pages. Ask how results are transmitted, who checks specimen quality and how the referring clinician learns whether the patient was accepted for care.
Costs and terms: public per-kit terms are a diagnostic purchase, not the total price of an internal SLIT program or the patient’s full course of care. This guide does not reproduce numeric terms. Request a current written quote covering utilized and unused kits, replacements, collection responsibilities, invoicing and patient charges. Partner eligibility, full contractual conditions and any minimum obligations are Not published in the cited pages; they remain unresolved until Wyndly confirms them.
Limits to resolve: the substantiated treatment scope in the homepage reviewed here is environmental allergy. A food-SLIT practice implementation offer is Not published in the cited partner page. Do not infer food capability, practice eligibility or local prescribing authority from consumer treatment descriptions, partner logos or patient testimonials. The referral service is a different clinical model from the local-prescriber programs above.
- Precontract question: which practice types and locations can enroll, and what are the collection, ordering and result-review responsibilities of each clinician?
- Precontract question: can our referring team receive consultation notes, acceptance or rejection decisions, prescription changes and a plan for patients who need in-person assessment?
Curex: distinguish clinic diagnostics from referral care
What is published: Curex has a live clinician-partners page with two distinct offers. Its diagnostics offer says a clinic can provide skin scratch allergy testing. Its referral offer says Curex provides allergy-test review, at-home immunotherapy and asthma care to referred patients. The company-authored About Curex page describes telemedicine assessment and prescribing, specialty-pharmacy preparation and ongoing clinical supervision. It also describes environmental and food allergy-drop services as patient offers.
Visible strength and fit: a practice that wants an external allergy-care pathway can evaluate a named referral service alongside an advertised clinic-testing option. The patient service describes several testing pathways and a clinician-led prescribing sequence. That may fit a practice seeking access to another care team without assuming responsibility for an internal drops program.
Workflow and training: keep the offers separate during procurement. Diagnostic enablement does not prove that Curex trains your clinicians to prescribe under a Curex protocol, and referral does not prove shared management. A complete clinic-testing implementation syllabus, staffing model, local-prescriber treatment curriculum, record-integration specification and service-level agreement are Not published in the cited pages. Ask which offer is currently enrolling practices and obtain a concrete handoff map.
Costs and terms: Curex publishes patient-plan information, but consumer subscription rates do not establish what a clinic pays for diagnostic enablement or any other practice service. Practice-program prices, referral commercial terms and a complete clinic agreement are Not published in the cited pages. Use the current patient pricing record for a patient counseling conversation, not as a proxy for a B2B quote. This guide does not reproduce promotional prices or the partner page’s revenue claims.
Limits to resolve: the public referral pathway does not establish that your practice can run Curex’s food service locally or that every referred patient can be treated remotely. Food allergy, anaphylaxis history, uncontrolled asthma, pregnancy and young children need individualized specialist and in-person assessment as appropriate. Request explicit acceptance criteria, what happens when remote care is unsuitable and how treatment decisions return to the referring clinician. Company scale and marketing assertions are not comparative efficacy evidence.
- Precontract question: are we purchasing diagnostic implementation, referring to a treating clinician, or doing both, and who signs each test order and treatment prescription?
- Precontract question: what specialist or local assessment is required for complex patients, and who coordinates that assessment and shares the resulting plan?
Serologix: formulation support and ordering, not a presumed turnkey clinic
What is published: Serologix describes allergen-immunotherapy compounding services for medical practices. Its SLIT page says treatment sets are patient-specific and compounded to the ordering physician’s specifications. It describes web-based ordering and company-developed cross-reactivity and biocompatibility tools. The About page says an allergy/immunology specialist and a PharmD are available to clients for formulation consultation.
Visible strength and fit: a practice with its own clinical expertise and follow-up model can evaluate a focused ordering-and-formulation service. The public description separates physician specifications from compounding and offers access to formulation consultation. This is a narrower, potentially relevant procurement model for practices that do not need a new patient referral pathway.
Workflow and support: the ordering physician defines the treatment set; the public service describes preparing that set and facilitating order entry. The published consultation scope is formulation, not a promise that Serologix diagnoses patients, takes over longitudinal care or operates a full clinical training program. A formal prescriber-training curriculum, practice-growth package and patient-management service are Not published in the cited pages. Ask for an order demonstration, how the tools handle incompatibility concerns and who approves a proposed change.
Costs and terms: complete SLIT practice pricing, recurring charges, onboarding costs and a practice-specific clinical service agreement are Not published in the cited pages. The website includes general sale terms, including price confirmation and additional delivery charges, but those are not enough to define clinical support, refill management or continuity. Obtain a named contracting and dispensing entity, state-specific eligibility and an itemized quote before proceeding.
Limits to resolve: Serologix’s statements about use of licensed extracts and compliance with a USP standard are company statements about inputs and preparation. They are not independent certifications, FDA approval of the final oral product or evidence that ordering software selects appropriate therapy for a patient. A food-allergy implementation program is Not published in the cited public SLIT and About pages. Do not assume food scope or broader clinical capabilities from the availability of compounding.
- Precontract question: which services are formulation consultation, which are dispensing, and which clinical duties are explicitly excluded?
- Precontract question: how are physician specifications, compatibility alerts, approved revisions and the dispensed product documented for our medical record?
- Serologix — Sublingual Immunotherapy Compounding
- Serologix — Company Info and Service Terms
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
- FDA — Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (January 2018)
Environmental candidacy is not a blanket food-allergy protocol
The inhalant-immunotherapy guideline supports offering or referring for immunotherapy when allergic rhinitis, with or without allergic asthma, is inadequately controlled by medical treatment or avoidance, or when a patient prefers immunomodulation. Selection combines clinical history with relevant testing. Sensitization on a panel is not, by itself, proof that an allergen causes the patient’s symptoms. The guideline recommends limiting treatment to clinically relevant allergens supported by history and testing.
The cited guideline recommends not initiating immunotherapy during pregnancy, with uncontrolled asthma, or when a patient cannot tolerate injectable epinephrine. Assess asthma before starting and reassess for loss of control during care. Anaphylaxis history, beta-blocker use, systemic immunosuppression and eosinophilic esophagitis for SLIT are separate factors for which a clinician may choose not to initiate treatment. Difficulty administering epinephrine requires assessment and education; it is not the same as inability to tolerate it. These are clinical decisions, not exclusions a sales workflow can settle.
For this practice-planning guide, use a conservative in-person specialist assessment gate for food or drug allergy, young children, pregnancy, anaphylaxis history and uncontrolled asthma before considering a home-treatment pathway. This is a proposed readiness precaution, not a claim that the inhalant guideline covers food or drug allergy or mandates the same visit format for every group. Its population is patients aged 5 years and older with inhalant allergic rhinitis, with or without allergic asthma; pregnancy recommendations distinguish initiation from continuation. Specialist assessment does not override a contraindication. Drug-allergy assessment is not a published program capability in these cited offers, and a remote service cannot be assumed suitable solely because drops can be administered at home.
Allergychoices and AllergyEasy publish food-program descriptions; Curex publishes a patient food-treatment service. The cited Wyndly partner offer and Serologix service pages do not establish food-SLIT practice implementation. Availability is not approval or a recommendation to start food treatment. Obtain separate specialist training, selection criteria, emergency planning and challenge arrangements where appropriate. Food avoidance changes require the treating specialist’s assessment; this page provides no dosing, escalation, restart or food-introduction instructions.
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
- Allergychoices — About the La Crosse Method Practice Protocol
- AllergyEasy — Become a Provider
- Curex — About Curex: Online Allergy and Asthma Clinic
- Wyndly — Partner FAQ
- Serologix — Sublingual Immunotherapy Compounding
- FDA — PALFORZIA
Prescriber versus vendor: assign responsibilities explicitly
For a local-prescriber model, pharmacist or advisor availability supports rather than replaces the prescribing clinician. For an external-care model, determine when the receiving clinician accepts the patient and assumes the treatment role; sending a referral is not evidence that the patient has been assessed or started care. For either model, a supplier’s software, fulfillment process or marketing package does not establish your team’s clinical competence.
On smaller screens, scroll the table horizontally to read every column.
| Task | Clinical responsibility to identify | Vendor contribution to confirm |
|---|---|---|
| Diagnosis and selection | Treating clinician documents relevant history, examination, testing, asthma status and patient-specific suitability. | Testing supplies, protocol materials or external assessment only if included in the actual service. |
| Treatment decision and consent | Prescriber selects the route, explains alternatives, benefits, risks and product status, and documents consent. | Patient education and protocol advice; confirm what is provided and who reviews understanding. |
| Prescription and revisions | Authorized prescriber approves the patient-specific order and any clinical changes. | Order tools, formulation consultation and preparation; identify the dispensing entity and approval handoff. |
| Counseling and monitoring | Treating clinician owns clinical follow-up, response assessment and reassessment when circumstances change. | Confirm pharmacy counseling, reminders, patient messages and what information returns to the clinician. |
| Reactions and urgent concerns | Name the clinician managing concerns and document a patient-specific emergency plan. Emergency services are not replaced by a vendor inbox. | Confirm urgent contact availability, routing and adverse-event communication; distinguish it from routine customer support. |
| Referral and continuity | Referring and treating clinicians agree who follows the patient and when local or specialist care is necessary. | Acceptance notices, consultation summaries, record access and a transition plan if the service ends. |
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
- Allergychoices — Clinical Practice Support
- AllergyEasy — Become a Provider
- Wyndly — Partner FAQ
- Curex — Immunotherapy Partners
- Curex — About Curex: Online Allergy and Asthma Clinic
- Serologix — Company Info and Service Terms
Request evidence and route-specific regulatory documentation
This comparison does not score treatment outcomes. Company descriptions establish available services. A testimonial, patient count, protocol history or claim of validation does not demonstrate that one program outperforms another. When evaluating a clinical paper, identify its formulation, route, patient selection, comparator, follow-up, missing data and outcome definition. An observational cohort cannot by itself establish comparative superiority, and evidence for a licensed tablet or a single-allergen product cannot automatically be transferred to a different compounded mixture.
Keep manufacturers, program vendors, treating clinicians and dispensing entities separate in your procurement file. A manufacturer listed as the source of an allergenic extract is not thereby the pharmacy dispensing your patient’s drops. Ask for the actual dispensing identity, applicable licenses, product documentation and route-specific rationale; the public offers do not independently verify these for your practice or state.
- Request the exact product and route, the evidence supporting the proposed use, and a patient explanation that distinguishes compounded drops from licensed sublingual tablets.
- Request documentation supporting the stated preparation standards, quality controls, formulation compatibility, labeling and handling for the product actually ordered.
- Ask the vendor and appropriate legal or regulatory advisor which requirements apply to the oral product. Do not accept a generic compounded-drug exemption or an injectable-allergen policy as the entire explanation.
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
- FDA — Allergen Extract Sublingual Tablets
- FDA — Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (January 2018)
- Allergychoices — Allergychoices Pharmacy
- Serologix — Sublingual Immunotherapy Compounding
Build the quote around the program, not the bottle price
No common all-in practice price is established by the public offers reviewed here. Allergychoices provides pharmacy prescription pricing by phone and publishes a no-contract service statement. AllergyEasy advertises start-up packages and financing without publishing the complete amounts and conditions in the cited pages. Wyndly publishes testing-kit commercial terms. Curex’s consumer plans are patient-service pricing, not a clinic-program quote. Serologix’s general sale terms are not a full SLIT practice fee schedule. These are different cost units, so a lowest-price comparison would be misleading.
Ask each business for a written quote for the same proposed practice workflow. Include patient eligibility, test method, training, routine and complex-case support, prescription processing, follow-up and discontinuation. Where an amount or term is absent, record Not published and then obtain written clarification. Do not infer reimbursement, margin, revenue or patient coverage from a sales statement.
- Practice costs: onboarding, protocol access, training, testing equipment and replenishment, software, administrative fees, recurring minimums and optional services.
- Patient costs: clinical assessment, testing, treatment preparation, shipping, follow-up, replacements and any separately billed consultation or subscription. Confirm insurance benefits rather than promising coverage.
- Commercial terms: contracting entity, scope, renewal, termination, exclusivity, unused inventory, refunds, delivered-product obligations and any financing agreement.
- Data terms: record access and export, patient communications, permitted data use, applicable privacy agreements and continuity when a clinician or vendor leaves.
- Service commitments: response channels, support hours, urgent escalation, rejected referrals, prescription corrections, refill review and responsibilities when a patient stops responding.
Questions to take to a discovery call
A useful answer is a document, demonstration or named responsibility, not simply “turnkey,” “safe,” “supported” or “no overhead.” Choose the offer that matches the care model your practice can actually deliver, with its strengths and unresolved limits visible. If the required capability is Not published and cannot be confirmed, do not build your implementation plan around it.
- Which current offer are you proposing: education and local prescribing, practice diagnostics, formulation and fulfillment, or referral to your clinicians? Which named entity provides each component?
- Is our specialty, prescriber credential, location and patient population eligible today? What separate enrollment or training is required for environmental versus food care?
- May we review the training syllabus, clinical selection policy, consent materials and escalation process before enrollment? How is staff competence assessed?
- Can you walk through a de-identified case from history and testing to the approved order, dispensed product, follow-up and a request to change treatment?
- Who signs prescriptions and changes, and who sees patients when remote assessment is unsuitable? How do we know an external referral was accepted?
- What support is pharmacist formulation advice, physician consultation, patient service or emergency care? Which response commitments are written into the agreement?
- Which costs are practice fees, patient charges or pharmacy charges? What is included, optional, recurring or due when a program or patient stops?
- Which evidence applies to this formulation and patient population? What cannot be concluded from your company outcomes or general SLIT studies?
- What regulatory rationale applies specifically to the oral product? Can we review dispensing identity, relevant licenses and product quality documentation?
- What records do we receive, how are adverse events communicated and how do patients transition to another clinician if the service ends?
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
- Allergychoices — Our Service Approach
- AllergyEasy — Become a Provider
- Wyndly — Partner FAQ
- Curex — Immunotherapy Partners
- Serologix — Company Info and Service Terms
- FDA — Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (January 2018)
Frequently asked questions
Which of these offers actually helps a local practice prescribe allergy drops?
Allergychoices publishes protocol-based practice support and AllergyEasy publishes a testing-and-prescribing program for local providers. Serologix publishes patient-specific compounding and order tools for an ordering physician, rather than a complete clinic implementation program. Wyndly’s verified partner page describes office testing followed by review from Wyndly doctors; Curex separately describes clinic testing and external referral care. Confirm enrollment and scope in writing rather than assuming these are equivalent turnkey programs.
Does Wyndly have a real provider or partner offer?
Yes. The live Wyndly Partner FAQ offers allergy testing in a partner office, a trial-kit pathway and result review with patients by Wyndly doctors. That substantiates a testing-partner and external-care pathway. It does not establish comprehensive training for partner clinicians to prescribe Wyndly treatment themselves. Full partner eligibility and local-prescriber program scope are Not published in the cited page and need direct confirmation.
Is Curex’s patient subscription the cost of a practice SLIT program?
No. A patient subscription and a clinic implementation quote are different purchases. Curex publishes a clinic diagnostics offer and a separate referral offer; complete practice charges and contractual terms are Not published in the cited partner page. Use its current patient pricing record to understand patient charges, not to estimate what your clinic would pay.
Does access to pharmacist or physician advice transfer the prescriber’s responsibility?
Not by itself. Advice about formulation or clinical questions does not establish that the advisor becomes the patient’s treating clinician. Identify who diagnoses, signs orders, approves changes, obtains consent and follows the patient. In an external-care model, confirm when the receiving clinician accepts the patient and what information returns to the referring practice.
Does a program’s use of FDA-approved extracts make the final drops FDA-approved?
No. Approval of an extract does not approve the final compounded oral drops, the mixture or its proposed use. FDA lists separately licensed allergen-extract sublingual tablets. Its January 2018 biologics guidance also distinguishes biologics from the compounded-drug exemptions in sections 503A and 503B, and its allergenic prescription-set policy in section III.C concerns subcutaneous immunotherapy, not oral SLIT. Obtain a route-specific explanation rather than treating a source-extract claim as final-product approval.
Can an environmental drops program be used as a food-allergy program?
Not on the basis of environmental-program enrollment alone. Food allergy requires a separate specialist assessment, patient-selection process, appropriate supervision and emergency planning. Some businesses publish food-service descriptions, but those descriptions do not establish that your clinicians are trained or authorized to deliver the service locally. A licensed food oral-immunotherapy product is also not approval of compounded food SLIT. Do not change food avoidance or introduce a food without the treating specialist’s direction.
What does Not published mean in this comparison?
It means the specific fact was not found in the cited public pages checked on October 12, 2026. It is not a claim that the service or term does not exist. Ask for current written confirmation of eligibility, service scope, education, prices and obligations. An accessible marketing page does not establish that your practice can enroll today.
Which program has the best outcomes?
This source set does not establish a comparative outcome ranking. Public provider offers are evidence of services, not independent head-to-head effectiveness. Clinical results must be interpreted for the actual formulation, route, population and study design; observational data, testimonials and scale claims do not demonstrate that one program is superior. Select a suitable care model and evaluate the evidence for the proposed treatment with the responsible clinician.
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
- Allergychoices — About the La Crosse Method Practice Protocol
- AllergyEasy — Become a Provider
- Wyndly — Allergy Shot Alternative with Sublingual Treatment Plans
- Curex — About Curex: Online Allergy and Asthma Clinic
- Serologix — Sublingual Immunotherapy Compounding
Who needs additional assessment before a home-treatment pathway?
The inhalant guideline concerns allergic rhinitis, with or without allergic asthma, in patients aged 5 years and older. It recommends not initiating immunotherapy during pregnancy, with uncontrolled asthma, or when the patient cannot tolerate injectable epinephrine, and requires asthma assessment and competence to recognize and manage anaphylaxis. Anaphylaxis history, beta-blocker use, systemic immunosuppression and eosinophilic esophagitis for SLIT are separate discretionary noninitiation considerations. This guide proposes a conservative in-person specialist assessment gate for food or drug allergy, young children, pregnancy, anaphylaxis history and uncontrolled asthma; that precaution is not a guideline mandate for a universal visit format. Food and drug allergy are outside the inhalant guideline’s scope. The treating clinician determines the necessary care setting and distinguishes starting therapy during pregnancy from reassessing existing maintenance treatment.
Regulatory scope
A small number of sublingual immunotherapy (SLIT) tablets are FDA-approved for specific allergens. Personalized allergy drops are compounded by a pharmacy for each patient and prescribed off-label — a long-standing, legitimate practice with decades of use, and SLIT is a first-line prescription approach in much of Europe. Compounded allergy drops are not FDA-approved, but they are created using FDA-approved allergenic extracts, the same as in allergy shots. Off-label does not mean unsafe or experimental.
Discuss practice onboarding
Ask Allergychoices about its published education, support and prescription workflow.
Sources
- Allergychoices — About the La Crosse Method Practice Protocol
Company description of patient-specific protocol access and environmental, food and preseasonal treatment options.
- Allergychoices — Our Service Approach
Original practice-support offer: diagnostics, clinical support, marketing, pharmacy option and the published no-contract statement.
- Allergychoices — Clinical Practice Support
Published pharmacist and physician-advisor support, order management, patient tracking and documentation.
- Allergychoices — Allergychoices Pharmacy
Company-described named-patient prescription preparation, counseling, lot tracking and prescription pricing on request by phone.
- AllergyEasy — Become a Provider
Original provider intake, optional testing, local prescribing, faxable forms, compounding-pharmacy shipment, support materials and start-up/financing offer.
- AllergyEasy — Current Program Homepage
Current company description of its universal-serum approach, optional testing and provider offer.
- Wyndly — Partner FAQ
Live original provider-facing offer: office allergy testing, trial-kit pathway, review by Wyndly doctors and public kit commercial terms.
- Wyndly — Allergy Shot Alternative with Sublingual Treatment Plans
Original patient offer: doctor-guided telehealth, environmental-allergen treatment, delivered therapy and drops/tablet descriptions.
- Wyndly — Frequently Asked Questions
Original consult and contact pathway and publicly visible provider-question categories.
- Curex — Immunotherapy Partners
Original clinician page distinguishes clinic skin-testing enablement from referral for test review, at-home immunotherapy and asthma care.
- Curex — About Curex: Online Allergy and Asthma Clinic
Company-authored patient-service descriptions: environmental and food drops, testing pathways, telemedicine prescribing and specialty-pharmacy preparation.
- Curex — Current Patient Pricing Reference
Patient-plan cost reference, identified by the current company About page and editorial checklist; not evidence of B2B practice prices. No rates, numeric plan terms or coverage promises reproduced.
- Serologix — Sublingual Immunotherapy Compounding
Original description of patient-specific treatment sets to ordering-physician specifications and electronic ordering with formulation tools.
- Serologix — Company Info and Service Terms
Original medical-practice compounding offer, allergy/immunology specialist and PharmD formulation consultation, contact details and general sale terms.
- Gurgel et al. — Executive Summary of Clinical Practice Guideline on Immunotherapy for Inhalant Allergy (2024)
Original guideline publication: candidacy, clinically relevant tested allergens, asthma assessment, pregnancy/noninitiation, anaphylaxis capability, route education and SLIT-specific eosinophilic-esophagitis considerations.
- FDA — Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (January 2018)
Original FDA guidance. Section II.C excludes biologics subject to licensure from 503A/503B compounded-drug exemptions; section III.C concerns licensed allergenic extracts for subcutaneous prescription sets. Not evidence of an oral-SLIT exemption, approval or universal safety guarantee.
- FDA — Allergen Extract Sublingual Tablets
Original FDA list of licensed sublingual-tablet products and allergic-rhinitis/conjunctivitis treatment context.
- FDA — PALFORZIA
Original FDA food oral-immunotherapy product description: mitigation of accidental peanut exposure reactions, continued peanut avoidance and not emergency treatment.
